

Vincent Esnault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5945633/publications.pdf>

Version: 2024-02-01

91
papers

4,570
citations

126858

33
h-index

110317

64
g-index

100
all docs

100
docs citations

100
times ranked

4659
citing authors

#	ARTICLE	IF	CITATIONS
1	Low T Cell Responsiveness in the Early Phase of COVID-19 Associates with Progression to Severe Pneumonia in Kidney Transplant Recipients. <i>Viruses</i> , 2022, 14, 542.	1.5	3
2	Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1881-1887.	1.4	12
3	Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	18
4	Visceral fat is associated to the severity of COVID-19. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154440.	1.5	100
5	Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1021-1024.	2.3	52
6	Proteinuria as a Biomarker for COVID-19 Severity. <i>Frontiers in Physiology</i> , 2021, 12, 611772.	1.3	19
7	Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy. <i>Kidney International Reports</i> , 2021, 6, 1183-1188.	0.4	16
8	Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients. , 2021, 9, e002512.		8
9	Regulation of Monocytes/Macrophages by the Renin-Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6009.	1.8	7
10	Immune checkpoint inhibitors-induced nephropathy: a French national survey. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3357-3364.	2.0	8
11	Extracellular fluid volume: A suitable indexation variable to assess impact of bariatric surgery on glomerular filtration rate in patients with chronic kidney disease. <i>PLoS ONE</i> , 2021, 16, e0256234.	1.1	2
12	Cohort study: Outcomes of kidney transplantation in patients with prosthetic heart valves. <i>Transplant International</i> , 2021, 34, 2297-2304.	0.8	1
13	Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. <i>Frontiers in Immunology</i> , 2021, 12, 738788.	2.2	12
14	Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. <i>EBioMedicine</i> , 2021, 73, 103679.	2.7	67
15	Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R ⁻): A Case Series. <i>Transplantation Proceedings</i> , 2020, 52, 204-211.	0.3	9
16	Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses. <i>Frontiers in Immunology</i> , 2020, 11, 574997.	2.2	37
17	Personalized Medicine for PLA2R1-Related Membranous Nephropathy: A Multicenter Randomized Control Trial. <i>Frontiers in Medicine</i> , 2020, 7, 412.	1.2	6
18	QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1090-1097.	2.3	27

#	ARTICLE	IF	CITATIONS
19	Humoral and Cellular Response of Frontline Health Care Workers Infected by SARS-CoV-2 in Nice, France: A Prospective Single-Center Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 608804.	1.2	10
20	Obesity and COVID-19: ACE 2, the Missing Tile. <i>Obesity Surgery</i> , 2020, 30, 4615-4617.	1.1	48
21	High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1173-1182.	2.2	85
22	<p>Osmotic stress and mortality in elderly patients with kidney failure: a retrospective study</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 225-229.	1.3	4
23	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2019, 393, 1937-1947.	6.3	408
24	Rituximab bioavailability in primary membranous nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1423-1425.	0.4	35
25	The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again. <i>Cancers</i> , 2019, 11, 250.	1.7	2
26	Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	0.9	27
27	Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab. <i>Frontiers in Immunology</i> , 2019, 10, 3069.	2.2	65
28	Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 401-408.	3.0	87
29	FP441HEPARIN-FREE 4 HOUR STANDARD HEMODIALYSIS SESSIONS WITH CITRIC ACIDE CONCENTRATE (CITRASATE): A SINGLE CENTRE RETROSPECTIVE COMPARATIVE STUDY WITH ANALYSIS OF THE CONFOUNDING FACTORS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i183-i184.	0.4	0
30	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). <i>Kidney International</i> , 2018, 94, 1217-1226.	2.6	20
31	Longitudinal assessment of renal function in native kidney after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 1411-1418.	1.0	14
32	Determinants associated with the correction of glomerular hyper-filtration one year after bariatric surgery. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 1760-1766.	1.0	13
33	Perirenal fat thickness measured with computed tomography is a reliable estimate of perirenal fat mass. <i>PLoS ONE</i> , 2017, 12, e0175561.	1.1	38
34	Multiphasic effects of blood pressure on survival in hemodialysis patients. <i>Kidney International</i> , 2016, 90, 674-684.	2.6	46
35	Vitamin Eâ€œCoated and Heparin-Coated Dialyzer Membranes for Heparin-Free Hemodialysis: A Multicenter, Randomized, Crossover Trial. <i>American Journal of Kidney Diseases</i> , 2016, 68, 752-762.	2.1	29
36	Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1517-1533.	3.0	161

#	ARTICLE	IF	CITATIONS
37	Modulation of glucose metabolism by the renin-angiotensin-aldosterone system. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E435-E449.	1.8	91
38	Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy. <i>Biochimie</i> , 2015, 118, 104-115.	1.3	17
39	Malignancy and thrombotic microangiopathy or atypical haemolytic and uraemic syndrome?. <i>British Journal of Haematology</i> , 2014, 166, 802-805.	1.2	11
40	Constitutive activation of the renin-angiotensin system reduces visceral fat and improves glucose tolerance in mice. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 396-409.	1.0	5
41	Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2334-2342.	0.4	59
42	Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. <i>Clinica Chimica Acta</i> , 2013, 421, 213-218.	0.5	117
43	Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma. <i>Lung Cancer</i> , 2013, 82, 362-364.	0.9	38
44	Patients' Preferences Regarding Choice of End-Stage Renal Disease Treatment Options. <i>American Journal of Nephrology</i> , 2013, 37, 359-369.	1.4	23
45	Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1694-1701.	2.2	30
46	KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. <i>Nature Genetics</i> , 2012, 44, 456-460.	9.4	281
47	Carbapenem-resistant <i>Klebsiella pneumoniae</i> is associated with poor outcome in hemodialysis patients. <i>Journal of Infection</i> , 2012, 65, 318-325.	1.7	25
48	Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2218-2224.	0.4	26
49	A clinical score to predict 6-month prognosis in elderly patients starting dialysis for end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1553-1561.	0.4	268
50	Activation of normal neutrophils by anti-neutrophil cytoplasm antibodies. <i>Clinical and Experimental Immunology</i> , 2008, 90, 228-234.	1.1	95
51	Antineutrophil cytoplasm antibodies (ANCA) of IgA isotype in adult Henoch-Schönlein purpura. <i>Clinical and Experimental Immunology</i> , 2008, 95, 49-55.	1.1	62
52	The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: A 3-year, randomized, multicenter, double-blind, placebo-controlled study. <i>Clinical Therapeutics</i> , 2008, 30, 482-498.	1.1	35
53	What is the Value of Tc-99m Hydroxymethylene Diphosphonate Scintigraphy for the Etiological Diagnosis of Mild Rhabdomyolysis?. <i>Clinical Nuclear Medicine</i> , 2007, 32, 519-523.	0.7	6
54	An international opinion poll of well-educated people regarding awareness and feelings about organ donation for transplantation. <i>Transplant International</i> , 2007, 20, 512-518.	0.8	24

#	ARTICLE	IF	CITATIONS
55	Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 474-481.	3.0	113
56	Home Blood Pressure During Normal Pregnancy. <i>American Journal of Hypertension</i> , 2005, 18, 1178-1180.	1.0	31
57	High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. <i>American Journal of Kidney Diseases</i> , 2004, 44, 402-9.	2.1	65
58	Difference in antigenic determinant profiles between human and rat myeloperoxidase. <i>Clinical and Experimental Immunology</i> , 2003, 132, 505-508.	1.1	10
59	Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1362-1364.	0.4	19
60	Apoptosis: the central actor in the three hits that trigger anti-neutrophil cytoplasmic antibody-related systemic vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1725-1728.	0.4	13
61	Photopheresis affects the course of experimental allergic encephalomyelitis in Lewis rat. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 238-243.	0.7	7
62	Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2002, 18, 36-41.	0.7	16
63	Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 39-44.	0.4	41
64	Rats Injected with Syngenic Rat Apoptotic Neutrophils Develop Antineutrophil Cytoplasmic Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1764-1768.	3.0	44
65	International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). <i>American Journal of Clinical Pathology</i> , 1999, 111, 507-513.	0.4	539
66	Correspondence. <i>Journal of Immunological Methods</i> , 1999, 222, 219-220.	0.6	3
67	Alpha1-antitrypsin phenotypes and anti-neutrophil cytoplasmic auto-antibodies in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 1293-1298.	0.8	13
68	Effect of Protein A Immunoabsorption in Nephrotic Syndrome of Various Etiologies. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 2014-2017.	3.0	41
69	ANCA-positive vasculitis and alpha 1-antitrypsin deficiency: could free ANCA antigens released by neutrophils mediate vasculitic lesions?. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 249-251.	0.4	17
70	Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. <i>Clinical and Experimental Immunology</i> , 1997, 107, 127-134.	1.1	40
71	Recurrence of immunoglobulin A nephropathy with immunoglobulin A antineutrophil cytoplasmic antibodies following renal transplantation. <i>American Journal of Kidney Diseases</i> , 1997, 29, 125-131.	2.1	22
72	Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1997, 20, 45-48.	1.3	12

#	ARTICLE	IF	CITATIONS
73	TREATMENT OF GRAFT-VERSUS-HOST DISEASE BY EXTRACORPOREAL PHOTOCHEMOTHERAPY. Transplantation, 1997, 64, 49-54.	0.5	73
74	Alpha-1-antitrypsin phenotyping in ANCA-associated diseases: one of several arguments for protease/antiprotease imbalance in systemic vasculitis. Experimental and Clinical Immunogenetics, 1997, 14, 206-13.	1.4	27
75	Anti-Lactoferrin Autoantibodies: Relation between Epitopes and Iron-binding Domain. Journal of Autoimmunity, 1996, 9, 569-574.	3.0	8
76	Anti-Neutrophil Cytoplasm Antibodies in Patients with ACR Criteria for Polyarteritis Nodosa: Help for Systemic Vasculitis Classification?. Autoimmunity, 1995, 20, 33-37.	1.2	9
77	Anti-neutrophil cytoplasm antibodies and anti-glomerular basement membrane antibodies: Two coexisting distinct autoreactivities detectable in patients with rapidly progressive glomerulonephritis. American Journal of Kidney Diseases, 1995, 26, 439-445.	2.1	98
78	Does truly "idiopathic" crescentic glomerulonephritis exist?. Nephrology Dialysis Transplantation, 1994, 9, 630-636.	0.4	24
79	Autoantibodies to lactoferrin and histone in systemic vasculitis identified by anti-myeloperoxidase solid phase assays. Kidney International, 1994, 46, 153-160.	2.6	21
80	High immunoreactivity of lactoferrin contaminating commercially purified myeloperoxidase. Journal of Immunological Methods, 1994, 176, 23-31.	0.6	7
81	Absence of antineutrophil cytoplasmic antibodies in giant cell arteritis. Journal of Rheumatology, 1994, 21, 871-3.	1.0	12
82	Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney International, 1993, 43, 1329-1332.	2.6	181
83	Association of ANCA Isotype and Affinity with Disease Expression. Journal of Autoimmunity, 1993, 6, 197-205.	3.0	35
84	ANCA Anti-Idiotypic Antibodies and the Treatment of Systemic Vasculitis with Intravenous Immunoglobulin. Journal of Autoimmunity, 1993, 6, 207-219.	3.0	112
85	Anti-Idiotypic Antibodies to Anti-Myeloperoxidase Autoantibodies in Patients With Systemic Vasculitis. Journal of Autoimmunity, 1993, 6, 221-226.	3.0	20
86	Animal Models of Systemic Vasculitis. Journal of Autoimmunity, 1993, 6, 251-264.	3.0	36
87	Pulmonary-renal syndrome in association with anti-GBM and IgM ANCA. Lancet, The, 1992, 339, 1304.	6.3	10
88	Association of IgM with IgG ANCA in patients presenting with pulmonary hemorrhage. Kidney International, 1992, 41, 1304-1310.	2.6	47
89	Autoantibodies to myeloperoxidase in brown Norway rats treated with mercuric chloride. Laboratory Investigation, 1992, 67, 114-20.	1.7	24
90	IgG subclass distribution and relative functional affinity of anti-myeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. Immunology, 1991, 74, 714-8.	2.0	28

#	ARTICLE	IF	CITATIONS
91	Anti-neutrophil cytoplasm antibodies in patients with monoclonal gammopathies. Journal of Clinical & Laboratory Immunology, 1990, 32, 153-9.	0.1	25